Mon, Dec 29, 2014, 6:14 AM EST - U.S. Markets open in 3 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Bergamo Acquisition Corp. Message Board

  • ripking99 ripking99 Jul 8, 2013 5:16 PM Flag

    VSTA Opens the Door to Multiple Opportunities

    A great technology is one that not only fills important needs, but one that can be applied in more than one way to meet important needs. It gives the developer important flexibility in determining how to best address the marketplace, allowing them to avoid approaches that may be technically feasible but which involve low-margins or other problems. It can be the difference between a good idea that leads directly to financial success or a good idea that doesn’t get off the ground.

    VistaGen Therapeutics, a California-based biotech company, has developed such a technology, providing them multiple options for monetization. Using their proprietary stem cell technology, VistaGen has created their Human Clinical Trials in a Test Tube bioassay platform, allowing researchers to test new drug candidates against actual heart and liver cells right in the lab, well before going to the expense of further development. The advantage is the early identification of potential heart or liver toxicity issues prior to spending enormous amounts of money taking a candidate through clinical trials or even all the way to market.

    It’s a technology that gives VistaGen more than one approach to the market. The technology could be the basis for a proprietary screening service, potentially saving the pharmaceutical industry millions or even billions of dollars in misdirected investments. It could also represent a major purchase target, making VistaGen itself highly attractive as a possible takeover. But it’s a technology that also gives VistaGen the ability to take earlier drug candidates, previously shelved due to liver or heart toxicity issues, and rescue them, using their unique testing platform to modify the drugs, generating their own high-margin pipeline of safe drug candidates. Even moderate success at such a pipeline would be extraordinarily profitable.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube?, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical or biotechnology companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to unexpected safety issues relating to the heart or liver or adverse drug-drug interactions. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

      VistaGen's small molecule prodrug candidate, AV-101, has successfully completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.

      Sentiment: Strong Buy

      • 3 Replies to ripking99
      • VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.

        Sentiment: Strong Buy

      • VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.

        Sentiment: Strong Buy

      • Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

 
BGMO.PK
0.010.00(0.00%)Oct 3 12:47 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
V.F. Corporation
NYSEFri, Dec 26, 2014 4:02 PM EST
58.com Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST